Prelude Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Prelude Capital Management’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-333	Closed	-$7K	–	1972
2015 Q2	$7K	Buy	+333	New	+$5.27K	﹤0.01%	1599
2014 Q3	–	Sell	-1,083	Closed	-$21K	–	2297
2014 Q2	$21K	Hold	1,083	–	–	﹤0.01%	1713
2014 Q1	$19K	Buy	+1,083	New	+$17.8K	﹤0.01%	1706

Prelude Capital Management's CASC Position: Q1 2018 in Review

Prelude Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 79,155 shares — an estimated $293K sold.

Prelude Capital Management first reported a position in CASC in Q3 2013 and held it in 3 quarters. The position peaked at $293K in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Prelude Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Prelude Capital Management sold 79,155 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $293K.
Prelude Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q3 2013 and held it in 3 quarters.
Prelude Capital Management's Cascadian Therapeutics, Inc. position peaked at $293K in Q4 2017.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Prelude Capital Management's 13F filing for Q1 2018, filed 15 May 2018.